Hinova Pharmaceuticals Revenue
Biotechnology Research • 
Jinniu District, Sichuan, China • 21-50 Employees
Hinova Pharmaceuticals revenue & valuation
| Annual revenue | $7,500,000 |
| Revenue per employee | $327,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $24,000,000 |
| Total funding | No funding |
Key Contacts at Hinova Pharmaceuticals
Yiyun Dai
Associate Director Of Clinical Operations
Jing Li
Director
Company overview
| Headquarters | 科园南路5号, 蓉药大厦1栋4层附2、3号, 成都市, 四川省, CN |
| Phone number | +862885058465 |
| Website | |
| SIC | 283 |
| Keywords | Prostate Cancer, Cancer, Gout, Metabolic Disease, Innovative Drug, Hyperuricemia, Anti-Cancer Drug, Deuterated Drug R&D Platform |
| Founded | 2013 |
| Employees | 21-50 |
| Socials |
Hinova Pharmaceuticals Email Formats
Hinova Pharmaceuticals uses 5 email formats. The most common is {first name}.{last name}@company.com (e.g., john.doe@company.com), used 45.6% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name}@company.com | john.doe@company.com | 45.6% |
{first name initial}{last name}@company.com | {first name initial}doe@company.com | 22.3% |
{first name}@company.com | john@company.com | 15.1% |
{first name}{last name}@company.com | johndoe@company.com | 9.8% |
{first name}_{last name}@company.com | john_doe@company.com | 7.2% |
About Hinova Pharmaceuticals
Hinova (688302.SH) is an international and clinical-stage pharmaceutical company focused on developing new therapeutics for cancers and metabolic syndromes through PROTAC and deuteration technology. We are committed to the discovery and development of innovative drugs with global interests that meet the significant clinical needs. Hinova pharma has 4 core R&D platforms, which are PROTAC (PROteolysis Targeting Chimera) platform, deuteration platform, novel target discovery and validation platform, and lead compound optimization screening platform. We have submitted more than 200 PCT and national patents, with more than 60 patents granted in China and in the globe, such as the US, EU, and Japan. We have 10 innovative projects in the R&D stage, and 2 National Major Projects of “Significant New Drugs Creation “awarded by Ministry of Science and Technology of the People’s Republic of China. The company is led by a management team comprised of accomplished experts in the biotechnology and pharmaceutical industries. The core team members are mostly from the world's Top 500 pharmaceutical companies, with 2 national-level and several provincial-level experts. Among the pipeline and programs, HC-1119 has entered the global multicenter phase-III clinical trials for the treatment of castration-resistant prostate cancer. HP501 for the treatment of hyperuricemia and gout, the Phase-II clinical trial of which has been completed in China. The Phase-II clinical trial of HP558 which is potenially effective for esophageal cancer, has been approved by NMPA. HP518, an orally bioavailable chimeric degrader targeting AR, is in Phase-I clinical trials in Australia.
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
Hinova Pharmaceuticals has 1 employees across 1 departments.
Departments
Number of employees
Funding Data
Hinova Pharmaceuticals has never raised funding before.
Hinova Pharmaceuticals Tech Stack
Discover the technologies and tools that power Hinova Pharmaceuticals's digital infrastructure, from frameworks to analytics platforms.
JavaScript libraries
Reverse proxies
Programming languages
SSL/TLS certificate authorities
JavaScript libraries
Saudi Arabia
Romania
Germany
Frequently asked questions
4.8
40,000 users
